Haider Mahdi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10827645/publications.pdf

Version: 2024-02-01

713332 933264 26 467 10 21 citations h-index g-index papers 26 26 26 898 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Role of Frozen Section in Surgical Staging of Low Risk Endometrial Cancer. PLoS ONE, 2011, 6, e21912.	1.1	80
2	Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology, 2020, 156, 715-725.	0.6	74
3	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. Journal of Experimental Medicine, 2017, 214, 2715-2732.	4.2	67
4	Prognostic impact of marital status on survival of women with epithelial ovarian cancer. Psycho-Oncology, 2013, 22, 83-88.	1.0	45
5	Tumor size is an independent predictor of lymph node metastasis and survival in early stage endometrioid endometrial cancer. Archives of Gynecology and Obstetrics, 2015, 292, 183-190.	0.8	35
6	Suicide in women with gynecologic cancer. Gynecologic Oncology, 2011, 122, 344-349.	0.6	24
7	Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. Gynecologic Oncology, 2015, 136, 529-533.	0.6	19
8	Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecologic Oncology, 2015, 137, 239-244.	0.6	18
9	Pagetoid Adenocarcinoma In Situ of the Cervix With Pagetoid Spread Into the Vagina. Obstetrics and Gynecology, 2011, 118, 461-463.	1.2	13
10	The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. Journal of Gynecologic Oncology, 2016, 27, e19.	1.0	13
11	Disparities in treatment and survival between African American and White women with vaginal cancer. Gynecologic Oncology, 2011, 122, 38-41.	0.6	11
12	Peripartum Robotic-Assisted Laparoscopic Hysterectomy After Second-Trimester Pregnancy Loss With Placenta Increta. Obstetrics and Gynecology, 2013, 122, 440-444.	1.2	10
13	Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011. Gynecologic Oncology, 2016, 143, 334-345.	0.6	10
14	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Medicine, 2021, 13, 89.	3.6	10
15	Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers. Immunotherapy, 2021, 13, 1179-1192.	1.0	8
16	Disparities in cervical cancer in African American women: What primary care physicians can do. Cleveland Clinic Journal of Medicine, 2017, 84, 788-794.	0.6	7
17	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. JCO Precision Oncology, 2018, 2, 1-11.	1.5	6
18	Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study. International Journal of Gynecological Cancer, 2017, 27, 1155-1164.	1.2	5

#	Article	IF	CITATIONS
19	Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB) Journal of Clinical Oncology, 2018, 36, 1511-1511.	0.8	5
20	Computational features of TIL architecture are differentially prognostic of uterine cancer between African and Caucasian American women Journal of Clinical Oncology, 2021, 39, 5585-5585.	0.8	4
21	Targeting the immunosuppressive tumor microenvironment: Synergistic effect of low-dose IL12 in combination with dual immune checkpoint inhibition in a preclinical model of ovarian cancer Journal of Clinical Oncology, 2020, 38, 7-7.	0.8	3
22	In Reply. Obstetrics and Gynecology, 2013, 122, 1303-1304.	1.2	0
23	The Use of Clinical Grade Magnetic Beads to Deplete Immune Suppressive Elements from Autologous Peripheral Blood Hematopoietic Stem Cell Grafts Enhances T Cell Immune Responses Blood, 2008, 112, 2311-2311.	0.6	O
24	Second malignant neoplasms (SMN) in Cowden syndrome patients with underlying germline PTEN mutations Journal of Clinical Oncology, 2013, 31, 1527-1527.	0.8	0
25	Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?. Journal of Clinical Oncology, 2015, 33, 5595-5595.	0.8	0
26	Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic Journal of Clinical Oncology, 2018, 36, e18710-e18710.	0.8	0